News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

ALL CONTRIBUTIONS

Week In Review: Zai Lab To Raise Up To $845 Million In Hong Kong IPO
Zai Lab​ of Shanghai is conducting a Hong Kong IPO that is expected to raise up to $845 million, offering 12.3% of the company's expanded number of shares. On the Nasdaq Exchange, Zai has a market capitalization of $6.2 billion.
Read
Week In Review: Baidu Raising $2 Billion For New China Biopharma
Baidu, one of China's major internet/AI companies, is talking with investors about raising $2 billion to fund a new China drug development and diagnostics company. It believes the $2 billion fundraising will take two years to complete.
Read
Week In Review: I-Mab Partners CD47 With AbbVie In $2 Billion Deal
I-Mab out-licensed ex-China rights for lemzoparlimab, its anti-CD47 mAb, to AbbVie in a blockbuster $2 billion agreement. AbbVie also acquired right-of-first-refusal to two other CD47 molecules, which would each trigger a $500 million payment.
Read
Week In Review: Antengene Approved By Hong Kong Exchange For $200 Million IPO
Antengene, a three-year old Shanghai startup originally backed by Celgene, will conduct a Hong Kong IPO that is expected to raise $200 million. BeiGene acquired China rights to Bio-Thera's Avastin® biosimilar in an agreement worth up to $165 million.
Read
Week In Review: Innovent Out-Licenses Ex-China Rights For PD-1 To Lilly In $1 Billion Deal
Suzhou Innovent Bio expanded its 2015 alliance with Eli Lilly for Tyvyt®, Innovent's anti-PD-1 immunotherapy. In return for a $1+ billion package, Lilly will have an exclusive license to develop Tyvyt in ex-China markets.
Read
Week In Review: $2.5 Billion In Deals Including LianBio's Initial $719 Million In In-Licensings
LianBio, a new Princeton-Shanghai company, acquired China rights to two BridgeBio oncology assets in a $531.5 million agreement. BridgeBio will receive $26.5 million in upfront payments, plus up to $505 million in future milestones.
Read

STOCKS I FOLLOW

AXN Aoxing Pharmaceutical Company, Inc.
CRPNF China Pioneer Pharma Holdings Ltd.
CYIG CHINA YCT INTL GROUP
HCM Hutchison Chi-Med
ICLR Icon PLC
MCRPF MICROPORT SCIENTIFIC
MDCO The Medicines Company
MR Mindray Medical International Limited
NBY NovaBay Pharmaceuticals, Inc.
SCLN SciClone Pharmaceuticals, Inc.
WX WuXi PharmaTech Inc.
Load More

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications